---
title: "Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294684783.md"
description: "Expanded reimbursement under the New Technology Add-on Payment program is expected to increase accessibility to a unique dual seizure and delirium monitoring platform. This development will significantly benefit patients, as well as healthcare providers, by enhancing access to innovative healthcare solutions. The increase in reimbursement stands to impact a large number of individuals seeking improved monitoring and care, further highlighting the potential positive outcomes of this program expansion."
datetime: "2026-08-03T11:03:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294684783.md)
  - [en](https://longbridge.com/en/news/294684783.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294684783.md)
generator: "portal-rs"
---

# Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System

Expanded reimbursement under the New Technology Add-on Payment program is expected to increase accessibility to a unique dual seizure and delirium monitoring platform. This development will significantly benefit patients, as well as healthcare providers, by enhancing access to innovative healthcare solutions. The increase in reimbursement stands to impact a large number of individuals seeking improved monitoring and care, further highlighting the potential positive outcomes of this program expansion.

### Related Stocks

- [CBLL.US](https://longbridge.com/en/quote/CBLL.US.md)

## Related News & Research

- [CeriBell (NASDAQ:CBLL) CFO Sells $16,300.00 in Stock](https://longbridge.com/en/news/298081116.md)
- [Ceribell wins FDA clearance for AI epileptiform detection, artifact reduction in cloud portal](https://longbridge.com/en/news/295395640.md)
- [Neuro Event Labs wins CMS NTAP coverage for Nelli seizure monitoring system, up to USD 975 per case](https://longbridge.com/en/news/298310708.md)
- [FDA places partial clinical hold on Biohaven BHV-7000 epilepsy trial, halting new enrollment](https://longbridge.com/en/news/298574622.md)
- [UCB turns to art for ‘Expressing Epilepsy’ awareness campaign](https://longbridge.com/en/news/298336977.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**